Advertisement
The conference, organized by the Indian Podiatry Association (IPA), aimedto help podiatrists and researchers with an interest in foot disease to"update, interact, modernize and catch up with the advancing pace ofscientific development in the field of podiatry." Dr. Jiang's talk, titled"Umbilical Cord Mesenchymal Stem Cell and Clinical Application Prospects inDiabetic Foot Disease," outlined the promise of stem cells in the healing ofdiabetic wounds and diabetic foot pathology.
Advertisement
"I am excited to have had this opportunity to discuss the role that stemcell therapy can play in healing diabetic wounds and related foot conditions,"said Dr. Susan Jiang, speaking after the Conference. "India is one of thefirst countries to put forth clear and practical guidelines on the clinicaluse of stem cells. It has also been at the forefront in embracing this newtechnology, and utilizing its potential clinical applications. Together withleading clinicians in the field, Beike India is preparing a clinical trial ofstem cell treatment in diabetic foot disease. Our pilot studies in Chinasuggest that stem cell treatment will become a very practical and effectiveclinical intervention. We are happy to share our observations from our stemcell therapy studies with the Indian clinical community."
Dr. Jiang's presentation highlighted the results and techniques used inBeike's Diabetic Foot clinical study performed in China. In December 2008,Beike completed a prospective clinical study scientifically testing thetherapeutic value that autologous mononuclear stem cell therapy holds fordiabetic lower-limb ischemia. In this 12 month follow-up study, of the 324subjects who received stem cell therapy, 283 (87.3%) showed significantimprovements indicated by clinical indicator tests performed 3 times over thetreatment period. The mechanism for these improvements requires morescientific inquiry before it is fully understood, however, Dr. Jiang discussedhow the study's data supported the angiogenesis hypothesis, which states thatlocally injected stem cells can enhance the growth of new blood vessels inpoorly vascularized areas. The study collected angiographic, skin temperature,blood oxygen and other data to record the effects of possible angiogenesis. Dr.Jiang's presentation was well received by the doctors and specialists inattendance, some expressing interest in future stem cell therapycollaborations using Beike stem cell technology and protocols.
The conference's scientific sessions, like Dr. Jiang's, helpedparticipants to further their understanding of clinical care for patients withdiabetes and encouraged networking between the physicians and other foot careprofessionals in attendance. It also acted as a resource for participants toobtain up-to-date information on theory and management of diabetic footdisorders while serving to increase awareness of recent diabetic foot disorderresearch. The meeting emphasized the importance of incorporating effectivetreatment strategies for limb preservation based on available technologies andthe need for a multidisciplinary team approach.
About IPA
The Indian Podiatry Association (http://www.ipafootcare.com ) is anon-profit organization founded on 1st April, 2009 in New Delhi , India. Itspurpose and objective is to disseminate and impart knowledge, and promoteawareness of diabetic and non-diabetic foot care, cure and prevention. It alsoaims to provide scientific information on current podiatry research.
About Beike Biotechnology Company Limited
Beike Biotechnology (http://www.beikebiotech.com ) is China's leadingbiotechnology company. Its scientists have been focused on the development andcommercialization of adult stem cell therapies since 1999. The companycurrently produces a full line of stem cell products from umbilical cord, cordblood, and bone marrow stem cells. Beike's unique processing technologiesprepare the cells for use in treating a variety of serious medical conditionsincluding ataxia, brain injury, cerebral palsy, diabetic foot disease, lowerlimb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury, andoptic nerve pathologies.For more information, please contact: T. Gutmann Shenzhen Beike Biotechnology Company, Ltd. Shenzhen Hi-Tech Industrial Park Tel: +86-755-8630-9200 Email: [email protected] Web: http://www.beikebiotech.com
SOURCE Beike Biotech Company Limited
